Article

Carolyn Presley Discusses the Burden of Curative Lung Cancer Treatment

Author(s):

Carolyn Presley

Carolyn Presley, clinical fellow, geriatric oncology, Yale Cancer Center, Robert Wood Johnson Clinical Scholar, discusses a study looking at the burden of health care on patients undergoing curative lung cancer care.

Carolyn Presley, clinical fellow, geriatric oncology, Yale Cancer Center, Robert Wood Johnson Clinical Scholar, discusses a study looking at the burden of health care on patients undergoing curative lung cancer care.

Read more about the study.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
CURE spoke with Andy Guinigundo to discuss the role that biomarkers play for patients with breast cancer.
How Biomarker Testing Can Shape a Breast Cancer Treatment Plan
Colorectal cancer is on the rise among younger adults, although potential explanations for the cause of this trend are likely years away.
Colorectal Cancer on Rise in Young Adults, Answers May Be Years Away
Dr. Valerie Lee discussed emerging targeted therapies and personalized medicine approaches that are showing promise for those with gastrointestinal cancer.
How Personalized Medicine May Impact Gastrointestinal Cancer Treatment
Image of doctor.
Machine Learning Improves Transplant Risk Assessment in Myelofibrosis
Although late-stage kidney cancer generated poor survival rates for over two decades, significant progress is being made in the treatment of the disease.
Breaking Down Kidney Cancer Treatment Advancements and Providing Hope
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.
The Benefit of Clinical Trial Enrollment for Patients With Cancer
Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function.
NeuroSAFE Increases Erectile Function After Prostate Cancer Surgery
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
Raising Awareness of Financial Struggles Faced by AYA Cancer Survivors
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Metastatic Kidney Cancer Requires a Multidisciplinary Approach to Care
Image of woman.
Research Shines Light on Disparities Across Breast Cancer Care
Related Content
PGV001, a personalized cancer vaccine, induced immune responses across various cancer types like breast and urothelial cancer, as well as multiple myeloma.
April 5th 2025

Personalized Cancer Vaccine Generates Responses Across Cancer Types

Ryan Scott
PGV001, a personalized cancer vaccine, induced immune responses across various cancer types like breast and urothelial cancer, as well as multiple myeloma.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Illustratoin of lungs
April 2nd 2025

Camrelizumab Combo Doubles 5-Year Survival in Phase 3 Lung Cancer Trial

Spencer Feldman
Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a Phase 3 trial.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of lung.
March 31st 2025

COCOON Trial Regimen Reduces Dermatologic Side Effects in Mutated Lung Cancer

Spencer Feldman
The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 trial data showed.
Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in EGFR+ advanced or metastatic NSCLC: © SciePro - stock.adobe.com
March 31st 2025

First-line Rybrevant Combo Extends Survival in Advanced Lung Cancer

Ryan Scott
First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.